KBP-336

Phase 2Small molecule

KKeyBioscience AG

KBP-336 is one of 24 small molecule programs targeting Osteoarthritis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

OsteoarthritisActive, not recruiting

OsteoarthritisPhase 2

Active, not recruiting

Competition

Competitive Landscape

778 competitors in Osteoarthritis

#DrugCompanyPhaseTrials

Toradol

Roche

Preclinical

1 2

Cataflam

Platelet Rich Plasma

25 4

Voltaren

CCerimon Pharmaceuticals

Preclinical

4 5

Enbrel

IImmunex

Preclinical

2 6

Protonix

WWyeth-Lederle Vaccines

Preclinical

1 7

Paracetamol

GSK

Preclinical

4 8

Naproxen Sodium

Bayer

Preclinical

1 9

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—10

Ansaid

PPharmacia and Upjohn

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Osteoarthritis

NCT06833749

Clinical

Trials by Indication[1]

Osteoarthritis1 trial

Efficacy and Safety of KBP-336 in Obese Individuals with Osteoarthritis

Recruiting·KKeyBioscience AG·Phase 2·NCT06833749·600 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for KBP-336. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — KBP-336 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for KBP-336. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — KeyBioscience AG company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: KKeyBioscience AG

KBP-336

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Osteoarthritis1 trial

References

Drug Info

Quick Facts

Related News